Molika Ashford

1 week ago | genomeweb.com | Molika Ashford

NEW YORK – Presentations at last week's annual meeting of the American Association for Cancer Research suggest that there are still numerous stones unturned in terms of methods and biomarker targets for multi-cancer early detection (MCED).

2 weeks ago | 360dx.com | Molika Ashford

NEW YORK – Guardant Health this week heralded a slew of new data supporting its liquid biopsy tests presented at the annual meeting of the American Association for Cancer Research. Separately, the firm reported that its Q1 revenues grew 21 percent year over year, driven by growth in all of its business segments and prompting the firm to increase its full-year financial guidance.

2 weeks ago | precisionmedicineonline.com | Molika Ashford

NEW YORK – Veracyte is in the midst of an effort to prove out the minimal residual disease technology adopted with its acquisition of C2i Genomics last year, and said last week that new data presented at the European Association of Urology Congress have left it confident that it will be able to launch the test for bladder cancer monitoring in the first half of 2026. The C2i approach is tumor informed, akin to tests developed by firms like Natera, Inivata (part of NeoGenomics), and others.

2 weeks ago | genomeweb.com | Molika Ashford

NEW YORK – Guardant Health this week heralded  a slew of new data supporting its liquid biopsy tests presented at the annual meeting of the American Association for Cancer Research. Separately, the firm reported that its Q1 revenues grew 21 percent year over year, driven by growth in all of its business segments and prompting the firm to increase its full-year financial guidance.

2 weeks ago | genomeweb.com | Molika Ashford

NEW YORK – New data presented at the annual meeting of the American Association for Cancer Research this week has further cemented the value of Personalis' ultrasensitive minimal residual disease (MRD) platform in colorectal cancer, with other studies continuing to add evidence for superiority of the approach over more targeted test platforms.